Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome*
References (33)
- et al.
Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant
J Pediatr
(1990) - et al.
Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial
J Pediatr
(1991) - et al.
Exogenous human surfactant for treatment of severe repiratory distress syndrome: a randomized clinical trial
J Pediatr
(1985) - et al.
Effects of a protein-free synthetic surfactant on the survival and pulmonary function of preterm lambs
J Pediatr
(1985) - et al.
Artificial surfactant therapy in hyaline membrane disease
Lancet
(1980) - et al.
Medical management of small pretern babies with symptomatic patent ductus arteriosus
J Pediatr
(1978) Radiology of hyaline membrane disease, transient tachypnea of the newborn, and bronchopulmonary dysplasia
- et al.
Bronchopulmonary dysplasia: the pulmonary pathologic sequel of necrotizing bronchiolitis and pulmonary fibrosis
Hum Pathol
(1976) - et al.
Prophylactic treatment of very premature infants with human surfactant
N Engl J Med
(1986) Ten centre trial of artificial surfactant (artificial lung expanding compound) in very premature babies
Br Med J
(1987)
Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial
Pediatrics
New treatment methods in idiopathic respiratory distress syndrome: replacement of surface active material
Clinics Crit Care Med
Effects of two rescue doses of Exosurf Pediatric in 419 700–1350 gram infants
Pediatr Res
Lung function in prematurely delivered rabbits treated with a synthetic surfactant
Am Rev Respir Dis
Pulsating bubble technique for evaluating pulmonary surfactant
J Appl Physiol
Cited by (174)
Synthetic surfactants
2023, Seminars in Fetal and Neonatal MedicinePhysiological fluid interfaces: Functional microenvironments, drug delivery targets, and first line of defense
2021, Acta BiomaterialiaCitation Excerpt :Insufficient LS production in premature infants may lead to infantile respiratory distress syndrome (IRDS) [324,325]. Since the early 1990s IRDS is routinely treated by administration of exogenous LS replacements through the breathing tube, which has significantly reduced IRDS mortality [363,364]. Purely synthetic analogues remain hampered by difficulties to produce functional recombinant SPs [365,366].
Preterm Intraventricular Hemorrhage/Posthemorrhagic Hydrocephalus
2018, Volpe's Neurology of the NewbornNebulization of mycophenolate mofetil inhalation suspension in rats: Comparison with oral and pulmonary administration of Cellcept<sup>®</sup>
2013, International Journal of PharmaceuticsCitation Excerpt :The development of pulmonary formulations is typically restricted by the excipients and their amounts (Pilcer and Amighi, 2010; Weers et al., 2010). Two surfactants, DPPC and tyloxapol, were chosen in the present study because of their approved amounts, 108 mg and 8 mg, respectively, (Long et al., 1991) and their physicochemical properties, which should enhance the migration of MMF to the lung peripheral region after deposition (Ganguly et al., 2008). The emulsion template process is based on the formation of a nano- or micro-emulsion followed by solvent evaporation leading to the precipitation of nanoparticles or microparticles in the aqueous phase.
Respiratory Disorders of the Newborn
2008, Pediatric Respiratory MedicineSplitting of a two-dimensional liquid plug at an airway bifurcation
2016, Journal of Fluid Mechanics
- *
Supported by funds from Burroughs Wellcome Co.